Hôpital Européen Georges Pompidou
Paris, 75015, France
NCT Number: NCT05271981
Uterine leiomyomas (or fibroids) are a common disease (30% of women over 35 years of age) in women of childbearing age and can cause various symptoms such as menometrorrhagia, dysmenorrhoea, pelvic pain and heaviness, and infertility.
Uterine artery embolisation, first used in France in 1990, is a safe, effective and less invasive therapeutic technique than surgical treatment (myomectomy or hysterectomy), particularly in the case of numerous and large fibroids. This technique is validated by the French National College of Gynaecologists-Obstetricians (CNGOF) as an alternative treatment for women who do not wish to become pregnant (grade A recommendation), but at present there is little reliable data concerning fertility, the occurrence of pregnancy and the obstetrical prognosis after uterine artery embolisation for fibroids. A recent systematic review of the literature with meta-analysis published very recently showed that 40.5% of patients with a desire for pregnancy were able to become pregnant after embolisation (CI: 33.3%-48.2%) but that the rates of miscarriage, obstetric complications and low birth weight were not negligible (respectively 33.5% (95% CI: 26.3-41%), 25.4% (95% CI = 13-40.2%) and 10% (95% CI = 6.2-14.6%) (Ghanaati et al. 2020).
In France, uterine artery embolisation is performed in more than thirty centres in women who have completed their parental project. On the other hand, in the absence of consistent literature, it is performed in patients of childbearing age, when it represents the only acceptable alternative or in the event of contraindication or refusal of surgery by the patient. To our knowledge, there is no large-scale French study to date on the impact of embolisation on fertility and pregnancy outcomes.
The aim of this study is to compile a retrospective database of all cases of uterine artery embolisation for uterine pathology performed at the Georges-Pompidou European Hospital (HEGP) since 2007 and to assess the impact of embolisation on fertility in patients of childbearing age.
Looking for future studies?
Notify Me18 year–45 year
Female
Observational
Paris, 75015, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Data collection from the medical file of the patients
Call for collecting fertility data and obstetrical issues of the patients
Time frame: one year
Rate of live births after embolisation (percentage)
Time frame: one year
Time frame: one year
Assistance Publique - Hôpitaux de Paris
Other
Uterine Artery Embolization For Uterine Pathology: What Impact On Fertility?
Acronym: FERTI-EMBOL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04854707
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Barnaul, Russia
View Trial DetailsNCT07464275
Fertility Disorders, Genital Diseases
Toronto, Ontario, Canada
View Trial DetailsNCT03085433
Embryo Quality, Fertility Disorders
San Francisco, California, United States
View Trial DetailsNCT04942457
Adnexal Diseases, Anovulation
Berlin, Germany
View Trial Details